## Contents

**WJCC** World Journal of Clinical Cases

**Thrice Monthly Volume 10 Number 21 July 26, 2022**

### OPINION REVIEW

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>7187</td>
<td>Effects of glucocorticoids on leukocytes: Genomic and non-genomic mechanisms</td>
<td>Jia WY, Zhang JJ</td>
</tr>
</tbody>
</table>

### MINIREVIEWS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>7209</td>
<td>Helicobacter pylori infection and small intestinal bacterial overgrowth—more than what meets the eye</td>
<td>Dharan M, Wezny D</td>
</tr>
<tr>
<td>7215</td>
<td>Anatomy of the anterolateral ligament of the knee joint</td>
<td>Park JG, Han SB, Rhim HC, Jeon OH, Jang KM</td>
</tr>
</tbody>
</table>

### ORIGINAL ARTICLE

#### Clinical and Translational Research

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>7224</td>
<td>Molecular mechanisms of Biyu decoction as treatment for psoriasis: A network pharmacology and molecular docking study</td>
<td>Wang Z, Zhang HM, Guo YR, Li LL</td>
</tr>
<tr>
<td>7242</td>
<td>Expression of hepatocyte nuclear factor 4 alpha, wingless-related integration site, and β-catenin in clinical gastric cancer</td>
<td>Hu Q, Li LL, Peng Z, Yi P</td>
</tr>
</tbody>
</table>

#### Case Control Study

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>7256</td>
<td>Improved Pittsburgh Sleep Quality Index scores on first postoperative night achieved by propofol anesthesia in patients undergoing ambulatory gynecologic surgery</td>
<td>Hu CH, Chou WY</td>
</tr>
<tr>
<td>7265</td>
<td>Efficacy of Guhong injection versus Butylphthalide injection for mild ischemic stroke: A multicenter controlled study</td>
<td>Zhang WW, Xin J, Zhang GY, Zhai QJ, Zhang HM, Wu CS</td>
</tr>
</tbody>
</table>

#### Retrospective Study

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>7275</td>
<td>Clinical values of Barcelona Clinic Liver Cancer subgroup and up-to-7 criteria in intermediate stage hepatocellular carcinoma with transcatheter arterial chemoembolization</td>
<td>Lee SW, Peng YC, Lien HC, Ko CW, Tung CF, Chang CS</td>
</tr>
<tr>
<td>7285</td>
<td>Intervention effect of encouraging mental and programmed nursing of patients in interventional operating room on their compliance and bad moods</td>
<td>Chi RB, Cui YY, Mao HP</td>
</tr>
</tbody>
</table>
## Contents

**Thrice Monthly Volume 10 Number 21 July 26, 2022**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>7293</td>
<td>Preoperative neoadjuvant chemotherapy in patients with breast cancer evaluated using strain ultrasonic elastography</td>
<td>Pan HY, Zhang Q, Wu WJ, Li X</td>
</tr>
<tr>
<td>7302</td>
<td>Risk factors for delayed intracranial hemorrhage secondary to ventriculoperitoneal shunt: A retrospective study</td>
<td>Chen JC, Duan SX, Xue ZB, Yang SY, Li Y, Lai RL, Tan DH</td>
</tr>
<tr>
<td>7314</td>
<td>Sequential treatment of severe pneumonia with respiratory failure and its influence on respiratory mechanical parameters and hemodynamics</td>
<td>Niu BY, Wang G, Li B, Zhen GS, Weng YB</td>
</tr>
<tr>
<td>7324</td>
<td>Effects of alendronate sodium combined with InterTan on osteoporotic femoral intertrochanteric fractures and fracture recurrence</td>
<td>Wang KM, Wei SP, Yin XY, Meng QJ, Kong YM</td>
</tr>
<tr>
<td>7333</td>
<td>Correlation of magnetic resonance imaging quantitative parameters and apparent diffusion coefficient value with pathological breast cancer</td>
<td>Wang Z, Ren GY, Yin Q, Wang Q</td>
</tr>
<tr>
<td>7341</td>
<td>Risk factors for delirium after surgery for craniocerebral injury in the neurosurgical intensive care unit</td>
<td>Chen RY, Zhong CH, Chen W, Lin M, Feng CF, Chen CN</td>
</tr>
</tbody>
</table>

**Observational Study**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>7348</td>
<td>Effect of osteoarthritic knee flexion deformity correction by total knee arthroplasty on sagittal spinopelvic alignment in Indian population</td>
<td>Puthiyapura LK, Jain M, Tripathy SK, Puliappadamb HM</td>
</tr>
</tbody>
</table>

**Randomized Controlled Trial**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>7365</td>
<td>Comparison of involved-field intensity-modulated radiotherapy combined with S-1 vs radiotherapy alone for elderly patients with esophageal cancer</td>
<td>Liu LH, Yan MH, Di YP, Fu ZG, Zhang XD, Li HQ</td>
</tr>
</tbody>
</table>

**Randomized Clinical Trial**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
</table>

**META-ANALYSIS**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>7386</td>
<td>Impact of cancer on mortality rates in patients with sepsis: A meta-analysis and meta-regression of current studies</td>
<td>Xiang MJ, Chen GL</td>
</tr>
</tbody>
</table>
CASE REPORT

7397  Updated clinical and glycomic features of mannosyl-oligosaccharide glucosidase deficiency: Two case reports

7409  Solitary necrotic nodules of the liver with "ring"-like calcification: A case report

7415  Corticosteroid-induced bradycardia in multiple sclerosis and maturity-onset diabetes of the young due to hepatocyte nuclear factor 4-alpha mutation: A case report
   Sohn SY, Kim SY, Joo IS

7422  Essential thrombocythemia with non-ST-segment elevation myocardial infarction as the first manifestation: A case report
   Wang ZM, Chen WH, Wu YM, Wang LQ, Ye FL, Yin RL

7429  Extranasopharyngeal angiofibroma in children: A case report
   Yan YY, Lai C, Wu L, Fu Y

7438  Deep Sylvian fissure meningiomas: A case report

7445  Acute pulmonary embolism originating from upper limb venous thrombosis following breast cancer surgery: Two case reports
   Duan Y, Wang GL, Guo X, Yang LL, Tian FG

7451  Managing spondylitis tuberculosis in a patient with underlying diabetes and hypothyroidism: A case report
   Novita BD, Muliono AC, Wijaya S, Theodora I, Tjahjono Y, Supit VD, Willianto VM

7459  Ovarian mucinous tumor with mural nodules of anaplastic carcinoma: Three case reports

7467  Transcatheter arterial infusion chemotherapy and embolization for primary lacrimal sac squamous cell carcinoma: A case report
   Sun MH, Yi WD, Shen L, Zhou L, Lu JX

7474  Programmed cell death-1 inhibitor combination treatment for recurrent proficient mismatch repair/microsatellite-stable type endometrial cancer: A case report
   Zhai CY, Yin LX, Han WD

7483  Novel compound heterozygous mutation of SLC12A3 in Gitelman syndrome co-existent with hyperthyroidism: A case report and literature review
   Qin YZ, Liu YM, Wang Y, You C, Li LN, Zhou XY, Lv WM, Hong SH, Xiao LX

7495  Successful treatment of hyperglycemia with liraglutide in a hospitalized 27-year-old patient with schizophrenia: A case report
   Zhang L, Yu WJ, Zhu H, Li HF, Qiao J
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>7502</td>
<td>Refractory lymphoma treated with chimeric antigen receptor T cells combined with programmed cell death-1 inhibitor: A case report</td>
<td>Zhang CJ, Zhang JY, Li LJ, Xu NW</td>
</tr>
<tr>
<td>7509</td>
<td>Median arcuate ligament syndrome with retroperitoneal haemorrhage: A case report</td>
<td>Lu XC, Pei JG, Xie GH, Li YY, Han HM</td>
</tr>
<tr>
<td>7517</td>
<td>Novel frameshift mutation in the AHDC1 gene in a Chinese global developmental delay patient: A case report</td>
<td>Lin SZ, Xie HY, Qu YL, Gao W, Wang WQ, Li JY, Feng XC, Jin CQ</td>
</tr>
<tr>
<td>7523</td>
<td>Selective nerve block for the treatment of neuralgia in Kummell’s disease: A case report</td>
<td>Zhang X, Li ZX, Yin LJ, Chen H</td>
</tr>
<tr>
<td>7531</td>
<td>Traditional Chinese medicine manipulative reduction combined with percutaneous vertebroplasty for treating type III Kummell’s disease: A case report</td>
<td>Hao SS, Zhang RJ, Dong SL, Li HK, Liu S, Li RF, Ren HH, Zhang LY</td>
</tr>
<tr>
<td>7539</td>
<td>Differential diagnosis and treatment of foot drop caused by an extraneural ganglion cyst above the knee: A case report</td>
<td>Won KH, Kang EY</td>
</tr>
<tr>
<td>7553</td>
<td>Chronic urticaria associated with lung adenocarcinoma — a paraneoplastic manifestation: A case report and literature review</td>
<td>Jiménez LF, Castellón EA, Marenco JD, Mejia JM, Rojas CA, Jiménez FT, Coronell L, Osorio-Llanes E, Mendoza-Torres E</td>
</tr>
<tr>
<td>7565</td>
<td>Spinal giant cell-rich osteosarcoma-diagnostic dilemma and treatment strategy: A case report</td>
<td>Tseng CS, Wong CE, Huang CC, Hsu HH, Lee JS, Lee PH</td>
</tr>
<tr>
<td>7571</td>
<td>Primary clear cell sarcoma of soft tissue in the posterior cervical spine invading the medulla oblongata: A case report</td>
<td>Liu CC, Huang WP, Gao JB</td>
</tr>
<tr>
<td>7577</td>
<td>Pseudomonas aeruginosa-related effusive-constrictive pericarditis diagnosed with echocardiography: A case report</td>
<td>Chen JI, Mei DE, Yu CG, Zhao ZY</td>
</tr>
<tr>
<td>7592</td>
<td>Considerations of single-lung ventilation in neonatal thoracoscopic surgery with cardiac arrest caused by bilateral pneumothorax: A case report</td>
<td>Zhang X, Song HC, Wang KL, Ren YY</td>
</tr>
<tr>
<td>Page</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------</td>
</tr>
<tr>
<td>7599</td>
<td>Rare primary rectal mucosa-associated lymphoid tissue lymphoma with curative resection by endoscopic submucosal dissection: A case report and review of literature</td>
<td>Tao Y, Nan Q, Lei Z, Miao YL, Niu JK</td>
</tr>
<tr>
<td>7609</td>
<td>Differences in examination results of small anastomotic fistula after radical gastrectomy with afterward treatments: A case report</td>
<td>Lu CY, Liu YL, Liu KJ, Xu S, Yao HL, Li L, Guo ZS</td>
</tr>
<tr>
<td>7617</td>
<td>Baseline differences may impact on relationship between dietary tryptophan and risk of obesity and type 2 diabetes</td>
<td>Ren XH, Ye YW, He LP</td>
</tr>
</tbody>
</table>
ABOUT COVER

Editorial Board Member of World Journal of Clinical Cases, Rajesh Kumar Rajnish, MBBS, MS, Assistant Professor, Department of Orthopaedics, All India Institute of Medical Sciences, Bilaspur, Bilaspur 174001, Himachal Pradesh, India. duktiraj@gmail.com

AIMS AND SCOPE

The primary aim of World Journal of Clinical Cases (WJCC, World J Clin Cases) is to provide scholars and readers from various fields of clinical medicine with a platform to publish high-quality clinical research articles and communicate their research findings online.

WJCC mainly publishes articles reporting research results and findings obtained in the field of clinical medicine and covering a wide range of topics, including case control studies, retrospective cohort studies, retrospective studies, clinical trials studies, observational studies, prospective studies, randomized controlled trials, randomized clinical trials, systematic reviews, meta-analysis, and case reports.

INDEXING/ABSTRACTING

The WJCC is now abstracted and indexed in Science Citation Index Expanded (SCIE, also known as SciSearch®), Journal Citation Reports/Science Edition, Current Contents®/Clinical Medicine, PubMed, PubMed Central, Scopus, Reference Citation Analysis, China National Knowledge Infrastructure, China Science and Technology Journal Database, and Superstar Journals Database. The 2022 Edition of Journal Citation Reports® cites the 2021 impact factor (IF) for WJCC as 1.534; IF without journal self cites: 1.491; 5-year IF: 1.599; Journal Citation Indicator: 0.28; Ranking: 135 among 172 journals in medicine, general and internal; and Quartile category: Q4. The WJCC’s CiteScore for 2021 is 1.2 and Scopus CiteScore rank 2021: General Medicine is 443/826.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Ying-Yi Yuan; Production Department Director: Xiang Li; Editorial Office Director: Jin-Lei Wang.

NAME OF JOURNAL

World Journal of Clinical Cases

ISSN

ISSN 2307-8960 (online)

LAUNCH DATE

April 16, 2013

FREQUENCY

Thrice Monthly

EDITORS-IN-CHIEF

Bao-Gan Peng, Jerzy Tadeusz Chudek, George Kontogeorgos, Maurizio Serati, Ja Hyeon Ku

EDITORIAL BOARD MEMBERS

https://www.wjgnet.com/2307-8960/editorialboard.htm

PUBLICATION DATE

July 26, 2022

COPYRIGHT

© 2022 Baishideng Publishing Group Inc
Refractory lymphoma treated with chimeric antigen receptor T cells combined with programmed cell death-1 inhibitor: A case report

Cang-Jian Zhang, Jun-Yu Zhang, Lin-Jie Li, Neng-Wen Xu

Abstract

BACKGROUND
Diffuse large B-cell lymphoma (DLBCL) is a common aggressive non-Hodgkin's lymphoma (NHL), accounting for 30%-40% of adult NHL. Primary testicular (PT) lymphoma is an uncommon extranodal disease representing approximately 1%-2% of lymphoma. Approximately 30%-40% of patients are refractory to frontline therapy or relapse after complete remission. Refractory DLBCL responds poorly to other lines of chemotherapy, and experiences short-term survival.

CASE SUMMARY
We present a 41-year-old male patient who was diagnosed with PT-DLBCL. Further disease progression was observed after multiline chemotherapy. Chimeric antigen receptor T cells (CAR-T) therapy salvaged the patient. Unfortunately, a new mass was observed in the right adrenal area after six months. The patient was administered programmed cell death protein-1 (PD-1) inhibitor therapy and maintained progression-free survival at more than 17 mo of follow-up.

CONCLUSION
Our findings support the potential benefit of CAR-T combined with PD-1 inhibitor therapies in this type of relapsed and refractory PT-DLBCL.

Key Words: Refractory diffuse large B-cell lymphoma; Programmed cell death protein-1 inhibitor; Chimeric antigen receptor T cells; Case report

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Primary testicular diffuse large B-cell lymphoma (DLBCL) is an uncommon extranodal disease of lymphomas. Refractory DLBCL responds poorly to other lines of chemotherapy, and is associated with short-term survival. Herein, we report one rare case of chimeric antigen receptor T cells (CAR-T) combined with programmed cell-death protein-1 (PD-1) inhibitor to treat refractory DLBCL in a 41-year-old male. Our findings support the potential benefit of CAR-T combined with PD-1 inhibitor therapies in this type of refractory DLBCL.

Citation: Zhang CJ, Zhang JY, Li LJ, Xu NW. Refractory lymphoma treated with chimeric antigen receptor T cells combined with programmed cell death-1 inhibitor: A case report. World J Clin Cases 2022; 10(21): 7502-7508
URL: https://www.wjgnet.com/2307-8960/full/v10/i21/7502.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i21.7502

INTRODUCTION

Primary testicular lymphoma (PTL) is a rare lymphoma with a poor prognosis and poor response to conventional chemotherapy. PLT represents approximately 1%-2% of lymphomas[1]. Approximately 30%-40% of patients are refractory to frontline therapy or relapse after complete remission[2]. Chimeric antigen receptor T cells (CAR-T) have a significant effect on recurrent refractory lymphoma, with good effects on most clinical manifestations in the early stage but for a short duration. The use of programmed cell death protein-1 (PD-1) inhibitors improves tumor immunity in the microenvironment and the immune efficacy of CAR-T cells. It is unclear whether it has unique clinical and biological characteristics, and the therapeutic mechanism needs further study. Therefore, we report a case of primary testicular diffuse large B-cell lymphoma (PT-DLBCL) treated with a PD-1 inhibitor after CAR-T therapy. The clinicopathological characteristics and the mechanism of CRT-T combined with PD-1 inhibitor therapy are discussed based on relevant literature, which helps to improve clinical understanding.

CASE PRESENTATION

Chief complaints
A 41-year-old man with an 8-mo history of right testicular enlargement.

History of present illness
On June 29, 2018, he underwent right orchiectomy and right inguinal lymph node biopsy. He had no history of trauma, fever, or other complaints. Physical examination showed unilateral enlargement of the right testicle without any superficial lymph node enlargement. The patient received a right orchiectomy. The histopathological diagnosis of DLBCL (non-GCB) was rendered. Hematoxylin and eosin-stained sections showed diffuse proliferation of medium-sized round cells. Immunohistochemistry revealed that the neoplastic cells expressed CD19, CD20, CD79a, and CD21 and were negative for CD3, CD5, CD10, CyclinD1, and ALK. Ki-67 was positive in 80% of tumor cells. BCL-2 was positive in 80% of tumor cells. BCL-6 was partially positive. C-myc was positive in 60% of tumor cells (Figure 1). The patient was diagnosed with DLBCL (non-GCB) IV. On July 13, 2018, four cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) were given at the local hospital. A follow-up abdominal computed tomography (CT) scan showed that the lymph nodes continued to enlarge beside the right iliac vessels. On November 13, 2018, a positron emission tomography/CT (PET-CT) scan showed multiple enlarged lymph nodes (4.3 cm × 2.7 cm) beside the right iliac vessels (Figure 2A). Two cycles of R2-HyperCVADA (lenalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) were given. A treatment intensification strategy was applied, and second-Line R-DHAP (rituximab, dexamethasone, cytarabine, and cisplatin) was administered. On July 15, 2019, a follow-up PET-CT scan showed that, in addition to the right iliac vessels, the lymph nodes continued to enlarge (4.3 cm × 3.8 cm) (Figure 2B).

History of past illness
His past medical history included diabetes and cervical spondylosis.

Personal and family history
No personal or family history was available.
Zhang CJ et al. CAR-T combined with PD-1 inhibitor in the PT-DLBCL

![Image of histopathological microphotograph of primary testicular diffuse large B-cell lymphoma.](https://www.wjgnet.com/)

**Figure 1** Histopathological microphotograph of primary testicular diffuse large B-cell lymphoma. A: The basic structure of the testicle is destroyed, and there are a lot of lymphocytes infiltrating (magnification × 100); B: Hematoxylin and eosin stained sections showed diffuse proliferation of medium-sized round cells (magnification × 400); C-H: On immunohistochemistry, the neoplastic cells showed positive expression of CD20 (C), CD79a (D), BCL-2 (E), BCL-6 (F), C-myc (G); Ki67 staining showed almost 80% proliferation index (H).

---

**Physical examination**
Physical examination showed no palpable lymph nodes, organomegaly, or cutaneous lesions.

**Laboratory examinations**
The peripheral blood and biochemical parameters (liver and renal function and serum lactate dehydrogenase level) were within normal limits. Bone marrow (BM) smear and biopsy did not show evidence of involvement by lymphoma cells.

**Imaging examinations**
On November 13, 2018, a PET-CT scan showed multiple enlarged lymph nodes (4.3 cm × 2.7 cm) beside the right iliac vessels and a high standard uptake value (SUV) with a Deauville score of 18.4 (Figure 2A).

On July 15, 2019, a follow-up PET-CT scan showed that, in addition to the right iliac vessels, the lymph nodes continued to enlarge (4.3 cm × 3.8 cm). The SUV was high, with a Deauville score of 17. New viable lesions were found in the right adrenal gland, right seminal vesicle gland and surrounding prostate gland, and right groin (Figure 2B).

---

**FINAL DIAGNOSIS**
Based on the above findings, the final diagnosis was made as refractory PT-DLBCL, stage IVB.

---

**TREATMENT**
On July 24, 2019, the patient was transferred to the First Affiliated Hospital of Zhejiang University and treated with CAR-T cells at a dose of 5 × 10^6/kg. Lymph node size significantly reduced after CAR-T therapy. Unfortunately, in June 2020, an abdominal CT scan showed a new mass in the right adrenal area with a size of approximately 2.8 cm × 1.3 cm. On June 11, 2020, PD-1 blockade therapy with sintilimab (100 mg once every 3 wk) commenced. The mass shrank soon after the sintilimab injection.

---

**OUTCOME AND FOLLOW-UP**
A year later, a PET-CT scan showed no viable lesions (Figure 3). CAR copies were 9574.28 cells/L on July 6, 2021. He has maintained complete remission until now.

---

**DISCUSSION**
PTL is a hematological malignancy with a low clinical incidence of 0.26 cases per 100000 person-years [3]. PTL accounts for approximately 1%-7% of testicular malignancies and approximately 1%-2% of all
PTL is the most common lymphoma among males over 60 years of age. The most common histopathological DLBCL in PTL, which accounts for approximately 80%-90% of all PTLs, is called PT-DLBCL. The primary clinical manifestation of PT-DLBCL is a painless enlargement of testicular tissue with occasional fever and night sweats, and weight loss. PT-DLBCL is highly aggressive and has a poor prognosis, with a median survival of 1-2 years, especially in patients with late clinical stages (stages III-IV), usually presenting with systemic multivisceral involvement within 2 years.

The clinical characteristics of PT-DLBCL are low incidence, high aggressiveness and complex treatment, which may explain the lack of a standard treatment at present. The recommended conventional treatment is chemotherapy after orchiectomy, which cures 60%-70% of patients. However, a small number of patients have a poor response to treatment, with frequent recurrence and poor prognosis. Prognostic factors regarding testicular lymphoma have been suggested in several large retrospective reports. In 2003, the International Extranodal Lymphoma Study Group suggested that advanced age, advanced stage, a high IPI score, elevated lactate dehydrogenase, and the absence of surgery or radiation therapy were significantly associated with poor prognosis. In 2012, Richie found that first-line treatment with R-CHOP, IT-MTX and testicular radiotherapy could improve the prognosis, while non-GCB cell phenotypes had a worse prognosis than GCB cell phenotypes. In 2018, Ollila and Olszewski found that patients with B symptoms, intranodal lymphoma, and concurrent...

**Figure 2 Positron emission tomography/computed tomography scan.** A: Positron emission tomography/computed tomography (PET-CT) scan showed multiple enlarged lymph nodes (red arrows); B: Follow-up PET-CT scan showed that, beside the right iliac vessels, the lymph nodes continued to enlarge. New viable lesions were found in the right adrenal gland, right seminal vesicle gland and surrounding prostate gland, and right groin.
MYC, BCL-2, or BCL-6 rearrangements ("double hit" or "triple hit") generally have a poor prognosis\[^9\]. In this patient, advanced age, a high IPI score, elevated lactate dehydrogenase, and the fact that lymphoma persisted after multiple first-line chemotherapies suggested a poor prognosis. Therefore, second-line treatment can be selected according to 2021 NCNN guidelines\[^10\], and CAR-T treatment can be given in combination with therapy depending on the patient’s family’s economic situation.

In recent years, there has been an increase in tumor immunotherapy use, especially CAR-T, which have been widely used to treat hematological tumors. CAR-T has an efficiency of approximately 80% and an OS rate of 52% at 18 mo in refractory large B-cell lymphoma\[^11\]. The principle of CAR-T therapy is to genetically modify T lymphocytes to express a specific receptor (CAR) to target and bind specific antigens so that T cells can specifically recognize tumor cells and kill tumors\[^12\]. In contrast to T cells under normal conditions, CAR-T cell recognition bypasses the antigen presentation phase. It thus is not restricted by MHC molecules, preventing cancer cells from escaping immune system recognition due to the downregulation of tumor MHC molecules\[^13\]. CAR-T cell therapy can significantly improve the remission rate of relapsed refractory lymphomas, but some patients fail to achieve the desired outcome.

In the disease state, tumor cells upregulate the expression of immune checkpoints by immunosuppressive cells and bind to corresponding sites on T cells. This inhibits the killing activity of T cells and helps the cancer cells evade immune monitoring and attack from the body, thereby promoting their survival\[^14\]. PD-1 is an immune checkpoint protein expressed on T cells. PD-1 binding to the receptor induces phosphorylation, which inhibits downstream activation of the T-cell receptor, limits T-cell proliferation activity and reduces its killing effect on tumor cells. In addition, the immunosuppressive effect of PD-1 Limits T cells. It affects the function of other lymphocyte subsets, such as promoting the proliferation and immunosuppression of regulatory T cells (Tregs) and inhibiting the activity of B cells and natural killer cells. Therefore, blocking the PD-1/p55 pathway increases the number of T cells and enhances cytokine secretion and reduces Treg cells and BM-derived suppressor cells to alter the inhibitory tumor microenvironment\[^15\]. CAR-T cell therapy works by enhancing the antitumor capacity of T cells. The overexpression of immune checkpoints limits the lethality of T cells. Immune checkpoint inhibitors may enhance the efficacy of CAR-T cell therapy since the inhibition of immune checkpoint expression increases the antitumor ability of T cells. Studies such as that by Cherkassky proved that the inhibition of the PD-1 receptor could weaken the inhibition of the PD-1 pathway in CAR-T cells, thus enhancing the ability of CAR-T cells\[^16\]. A study showed that PD-L1 expression was upregulated in hepatocellular carcinoma cells exposed to GPC3 CAR-T cells, and the antitumor activity of CAR-T cells could be enhanced by the knockdown of the PD-1 gene\[^17\]. Chong et al\[^18\] reported a patient with refractory and recurrent DLBCL. He received a PD-1 inhibitor 28 d after CAR-T cell treatment, after which the tumor cells shrank significantly. The patient was followed up for 12 mo, at which point sustained remission was achieved\[^18\]. Wang et al\[^19\] also reported a case of refractory follicular lymphoma (FL) treatment. After 6 cycles of chemotherapy, the patient was diagnosed with refractory FL, and the results were poor. The patient was treated with CD19 CAR-T cells in combination with a reduced dose of nivolumab. To date, the patient has maintained CR for 16 mo.
Table 1 Pertinent literature

<table>
<thead>
<tr>
<th>Ref.</th>
<th>Date</th>
<th>Sex</th>
<th>Age (yr)</th>
<th>Diagnosis</th>
<th>Response</th>
<th>Follow-up time (mo)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chong et al[18]</td>
<td>2017</td>
<td>M</td>
<td>35</td>
<td>DLBCL</td>
<td>PR</td>
<td>12</td>
</tr>
<tr>
<td>Wang et al[19]</td>
<td>2019</td>
<td>F</td>
<td>70</td>
<td>FL</td>
<td>CR</td>
<td>10</td>
</tr>
<tr>
<td>Zhang et al[20]</td>
<td>2021</td>
<td>F</td>
<td>37</td>
<td>DLBCL</td>
<td>PR</td>
<td>17</td>
</tr>
<tr>
<td>Our case</td>
<td>2022</td>
<td>M</td>
<td>41</td>
<td>DLBCL</td>
<td>PR</td>
<td>12</td>
</tr>
</tbody>
</table>

M: Male; F: Female; FL: Follicular lymphoma; DLBCL: Diffuse large B cell lymphoma; PR: Partial complete remission; CR: Complete complete remission.

[19]. Zhang et al[20] showed a case of refractory DLBCL that developed disease progression after 12 wk of CAR-T cell treatment. Then, the patient was treated with a PD-1 inhibitor. To date, the patient has maintained CR[20]. Relevant literature reports were made by retrieving relevant literature at home and abroad (Table 1). In this article, the patient relapsed 6 mo after CAR-T cell therapy. PD-1 inhibitors were still effective, and CAR-T cells could still be detected in the patient 2 years later. These findings suggest that PD-1 inhibitors may affect the efficacy of CAR-T cell therapy in the tumor microenvironment of immune suppression.

CONCLUSION

CAR-T cells have been widely used to treat hematological malignancies, but their associated remission rates still need improvement. Immune checkpoint inhibitors can vastly alter the immunosuppressive microenvironment where CAR-T cells live, improving their proliferative activity and antitumor capacity and increasing the prognosis of relapsed refractory tumors. Even after the failure of CAR-T therapy, the choice of PD-1 inhibitor therapy may still be effective. Our center will continue to treat patients who have failed CAR-T therapy with PD-1 inhibitors to explore the therapeutic feasibility of this treatment option and to provide new treatment strategies for relapsed refractory lymphoma.

FOOTNOTES

Author contributions: Zhang CJ designed the report and wrote the paper; Li LJ collected the patient’s clinical data; Xu NW analyzed the data; Zhang JY revised the paper; all authors have read and approved the final version of this manuscript.

Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: China

ORCID number: Cang-Jian Zhang 0000-0001-8966-3545; Jun-Yu Zhang 0000-0002-1013-8172; Lin-Jie Li 0000-0003-2674-2996; Neng-Wen Xu 0000-0002-9543-8990.

S-Editor: Fan JR
L-Editor: A
P-Editor: Fan JR
REFERENCES


